[HTML][HTML] Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer
Advances in the treatment of non-small cell lung cancer (NSCLC) over the last decade have
predominantly involved the development of therapies directed at molecular targets such as …
predominantly involved the development of therapies directed at molecular targets such as …
[PDF][PDF] Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer
P Savas, B Hughes, B Solomon - Oncology - cdn.amegroups.cn
Advances in the treatment of non-small cell lung cancer (NSCLC) over the last decade have
predominantly involved the development of therapies directed at molecular targets such as …
predominantly involved the development of therapies directed at molecular targets such as …
[PDF][PDF] Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer
P Savas, B Hughes, B Solomon - Oncology - academia.edu
Advances in the treatment of non-small cell lung cancer (NSCLC) over the last decade have
predominantly involved the development of therapies directed at molecular targets such as …
predominantly involved the development of therapies directed at molecular targets such as …
[PDF][PDF] Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer
P Savas, B Hughes, B Solomon - Targeted Therapy for Lung Cancer … - fp.amegroups.cn
Advances in the treatment of non-small cell lung cancer (NSCLC) over the last decade have
predominantly involved the development of therapies directed at molecular targets such as …
predominantly involved the development of therapies directed at molecular targets such as …
Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer.
P Savas, B Hughes, B Solomon - Journal of Thoracic Disease, 2013 - europepmc.org
Advances in the treatment of non-small cell lung cancer (NSCLC) over the last decade have
predominantly involved the development of therapies directed at molecular targets such as …
predominantly involved the development of therapies directed at molecular targets such as …
Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer
P Savas, B Hughes, B Solomon - Journal of thoracic …, 2013 - pubmed.ncbi.nlm.nih.gov
Advances in the treatment of non-small cell lung cancer (NSCLC) over the last decade have
predominantly involved the development of therapies directed at molecular targets such as …
predominantly involved the development of therapies directed at molecular targets such as …
[HTML][HTML] Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer
P Savas, B Hughes, B Solomon - Journal of Thoracic Disease, 2013 - jtd.amegroups.org
Advances in the treatment of non-small cell lung cancer (NSCLC) over the last decade have
predominantly involved the development of therapies directed at molecular targets such as …
predominantly involved the development of therapies directed at molecular targets such as …
[引用][C] Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer
P Savas, B Hughes, B Solomon - Journal of Thoracic …, 2013 - espace.library.uq.edu.au
Advances in the treatment of non-small cell lung cancer (NSCLC) over the last decade have
predominantly involved the development of therapies directed at molecular targets such as …
predominantly involved the development of therapies directed at molecular targets such as …
Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer.
P Savas, B Hughes, B Solomon - Journal of Thoracic Disease, 2013 - europepmc.org
Advances in the treatment of non-small cell lung cancer (NSCLC) over the last decade have
predominantly involved the development of therapies directed at molecular targets such as …
predominantly involved the development of therapies directed at molecular targets such as …
Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer
P Savas, B Hughes, B Solomon - Journal of Thoracic Disease, 2013 - jtd.amegroups.org
Advances in the treatment of non-small cell lung cancer (NSCLC) over the last decade have
predominantly involved the development of therapies directed at molecular targets such as …
predominantly involved the development of therapies directed at molecular targets such as …